AUTHENTIC PRODUCTS
Only original pharmaceutical products that passed 3 stages of clinical trials.
GMP QUALITY
Our products are produced on GMP or state licensed factories.
15% CRYPTO DISCOUNT
15% discount for paying in BTC or other cryptocurrency.
PAYMENT BY CARD
Convenient Payment by Visa or MasterCard.
GUARANTEED DELIVERY
Guaranteed delivery times and clear Reshipment & Refund Rules.
PROMPT SHIPPING
Different shipping methods and same or next day shipping.
Neipilept®, Ceraxon® (CDP-Choline)
1 Reviews
Description
Dosage
Research
Reviews
📦 Save with the volume discount 📦
| Synonyms | Cognizin / Citicoline / Neipilept / NeurAxon / Somazina / Synapsine / Recognan |
| Form: | 5 vials of 4 ml / 10 sachets of 10 ml |
| Form description: | Transparent colorless liquid / Transparent colorless liquid with a strawberry smell. |
| Active ingredient: | Citicoline sodium |
| Excipients for vials: | Hydrochloric acid 1M or sodium hydroxide 1M to pH 6.5–7.1, water for injections to 4 ml. |
| Excipients for sachets: | Sorbitol, glycerol, methylparahydroxybenzoate, propylparahydroxybenzoate, dihydrate of sodium citrate, sodium saccharinate, strawberry flavor (strawberry essence 1487-SLucta), potassium sorbate, citric acid, purified water. |
| СAS Number: | 987-78-0 |
| ATC code: | N06BX06 |
| Pharmacological action: | Nootropic |
| Shelf life: | 3 years. Do not use it beyond the expiration date printed on the package. |
| Storage conditions: | Store in a dry, dark place at temperatures no higher than 30°C (86°F). Keep out of the reach of children. |
| Terms of release: | Over-the-counter |
| Manufacturer: | Takeda Pharmaceutical / Ferrer Internacional, Spain |
Ceraxon and Neipilept are pharmaceutical preparations of CDP-Choline, a choline-containing phospholipid. It is an essential nutrient that, according to research, plays a vital role in liver function, brain development, muscle control, and metabolism. While it is typically obtained through the diet, many choline-rich foods are also high in cholesterol. As a result, individuals who limit cholesterol intake may inadvertently reduce their choline consumption.
To help meet daily requirements, choline is available as a dietary supplement in various forms, including Ceraxon or Neipilept (CDP-choline) and Cereton (Alpha-GPC). Additionally, the use of certain nootropics such as Piracetam or Noopept may increase the body’s demand for choline, making supplementation more relevant in those contexts. However, choline supplementation should be approached thoughtfully and under medical supervision, as both deficiency and excessive intake can lead to adverse health effects.
CDP-Choline is not approved by the FDA as a prescription medication and is not intended to diagnose, treat, cure, or prevent any disease. For more details, please refer to the manufacturer’s instructions or peer-reviewed scientific literature.
Note: In accordance with FDA regulations, we do not provide information regarding medical indications or therapeutic uses of this compound on our website.
Due to FDA regulations, we cannot provide dosage recommendations for Ceraxon (CDP-Choline). Note that it has contraindications and adverse reactions. In the USA it can be used as a supplement only. For more information on Ceraxon, please refer to the translated official drug sheets linked below.
- M. Fioravanti and A. Buckley (2006). Citicoline (Cognizin) in the treatment of cognitive impairment.
- Gavrilova et al. (2011). Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome.
- Martynov et al. (2013). Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke.
- J. Nasiri, M. Kargar (2014). Combination of Citicoline and Physiotherapy in Children with Cerebral Palsy.
- Rubtsova et al. (2014). Study of efficiency of ceraxon in the treatment of lag psychomotor development of children with hypoxic-ischemic lesions of central nervous system.
- Secades et al. (2016). Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials.
- Mashin et al. (2017). Multicenter observational program for evaluation of the effectiveness of the Recognan (Citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology.
- Nemkova et al. (2018). Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline).
- Jasielski et al. (2020). Application of Citicoline in Neurological Disorders: A Systematic Review.
- D-L. Que, R. D. Jamora (2021). Citicoline as Adjuvant Therapy in Parkinson’s Disease: A Systematic Review.
- Nemkova et al. (2021). The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment.
- Al-Kuraishy et al. (2022). Citicoline and COVID-19: vis-à-vis conjectured.
5
Based on 1 Reviews
(1)
(0)
(0)
(0)
(0)
Thank you!
You will now receive regular updates from us!
Your coupon
You’re all set!
Check your email to get your free Biohacking Guide